Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139521 | 0.89 | L3MBTL1 (0.44) | L3MBTL1LMNANPSR1MEN1KMT2A | |
| SCHEMBL2137626 | 0.86 | AHR (0.41) | L3MBTL1AHRNPC1THRBCCR2 | |
| SCHEMBL2138480 | 0.86 | AHR (0.42) | AHRNPC1FFAR2 | |
| SCHEMBL2136512 | 0.85 | AHR (0.37) | L3MBTL1AHRCCR2FFAR2 | |
| SCHEMBL2135903 | 0.85 | HTT (0.46) | L3MBTL1LMNANPSR1MEN1KMT2A | |
| SCHEMBL2135766 | 0.85 | L3MBTL1 (0.45) | L3MBTL1LMNANPSR1MEN1KMT2A | |
| SCHEMBL2138644 | 0.85 | AHR (0.42) | AHRMEN1KMT2ANPC1CCR2 | |
| SCHEMBL2139189 | 0.84 | AHR (0.42) | AHRNPC1CCR2FFAR2 | |
| SCHEMBL2136499 | 0.84 | AHR (0.36) | L3MBTL1AHRCCR2 | |
| SCHEMBL2139572 | 0.82 | AHR (0.40) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2447265-A1 | NOVEL THIOPHENE CARBOXAMIDE DERIVATIVE AND MEDICINAL USE OF SAME | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | GCK, GCKR, HK2 | L3MBTL1 4632/4885AHR 3039/4885LMNA 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.